癫痫治疗中系统筛查抗癫痫药物不良反应能否改善健康结局:一项随机试验
该随机试验纳入809例中AEP评分≥45的222例未控制癫痫患者,干预组向医生提供AEP评分,对照组不提供,随访18个月。两组AEP和QOLIE-31评分均较基线改善,但组间无统计学显著差异,系统筛查不良反应未减轻毒性负担。
要点
- 系统筛查抗癫痫药不良反应未比常规医生治疗更降低毒性负担。
- 干预组与对照组AEP和QOLIE-31评分改善程度无显著组间差异。
- 该研究提供Class II证据,不支持常规使用AEP问卷额外筛查。
核心结论
- 与既往研究相反,使用AEP评分系统筛查抗癫痫药物不良反应未在常规医生治疗基础上降低毒性负担。
研究设计与样本
- 随机对照试验,连续纳入年龄≥16岁、癫痫未控制且AEP评分高的患者,在11个转诊中心随访18个月。
- 809例完成AEP问卷者中222例AEP评分≥45被随机分为干预组(n=111)和对照组(n=111),206例完成18个月随访。
主要发现
- 干预组AEP评分较基线平均下降6个月7.2%、12个月12.1%、18个月13.8%(p<0.0001)。
- 对照组AEP评分较基线平均下降6个月7.7%、12个月9.2%、18个月12.0%(p<0.0001)。
- QOLIE-31评分从基线至末次访视,干预组平均提高20.7%,对照组平均提高24.9%(p<0.0001)。
- 两个共同主要变量(AEP评分和QOLIE-31评分变化)的组间差异均无统计学意义。
临床怎么用
- 在常规癫痫诊疗中,额外系统收集AEP问卷未显示可进一步减轻抗癫痫药物毒性负担。
局限性
- 研究于2006-2009年开展,2019年回顾性注册,注册时机可能影响方法学透明度。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To determine whether systematic screening for adverse effects of antiepileptic drugs (AEDs) reduces toxicity burden and improves health-related quality of life in patients with epilepsy. METHODS: Consecutive patients with uncontrolled seizures aged ≥16 years and a high Adverse Event Profile (AEP) score were randomized to 2 groups and followed up for 18 months at 11 referral centers. AEP scores were made available to treating physicians at all visits in the intervention group, but not in the control group. Co-primary endpoints were changes in AEP scores and Quality of Life Inventory for Epilepsy-31 (QOLIE-31) scores. RESULTS: Of 809 enrolled patients able to complete the AEP questionnaire, 222 had AEP scores ≥45 and were randomized to the intervention (n = 111) or control group (n = 111). A total of 206 patients completed the 18-month follow-up. Compared with baseline, AEP scores decreased on average by 7.2% at 6 months, 12.1% at 12 months, and 13.8% at 18 months in the intervention group (p < 0.0001), and by 7.7% at 6 months, 9.2% at 12 months, and 12.0% at 18 months in controls (p < 0.0001). QOLIE-31 scores also improved from baseline to final visit, with a mean 20.7% increase in the intervention group and a mean 24.9% increase in the control group (p < 0.0001). However, there were no statistically significant differences in outcomes between groups for the 2 co-primary variables. CONCLUSIONS: Contrary to findings from a previous study, systematic screening for adverse effects of AEDs using AEP scores did not lead to a reduced burden of toxicity over usual physician treatment. ITALIAN MEDICINES AGENCY AIFA IDENTIFIER: FARM52K2WM_003. CLINICALTRIALSGOV IDENTIFIER: NCT03939507 (registered retrospectively in 2019; the study was conducted during the 2006-2009 period and registration of clinical trials was not a widely established practice when this study was initiated). CLASSIFICATION OF EVIDENCE: This study provides Class II evidence that the additional collection of formal questionnaires regarding adverse effects of AEDs does not reduce toxicity burden over usual physician treatment.
引用
- Franco V, Canevini MP, De Sarro G, et al. Does screening for adverse effects improve health outcomes in epilepsy? A randomized trial. Neurology. 2020. PMID: 32601123. doi:10.1212/WNL.0000000000009880
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。